» Articles » PMID: 27048815

Inhibition of Regulated Cell Death by Cell-penetrating Peptides

Overview
Publisher Springer
Specialty Biology
Date 2016 Apr 7
PMID 27048815
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Development of the means to efficiently and continuously renew missing and non-functional proteins in diseased cells remains a major goal in modern molecular medicine. While gene therapy has the potential to achieve this, substantial obstacles must be overcome before clinical application can be considered. A promising alternative approach is the direct delivery of non-permeant active biomolecules, such as oligonucleotides, peptides and proteins, to the affected cells with the purpose of ameliorating an advanced disease process. In addition to receptor-mediated endocytosis, cell-penetrating peptides are widely used as vectors for rapid translocation of conjugated molecules across cell membranes into intracellular compartments and the delivery of these therapeutic molecules is generally referred to as novel prospective protein therapy. As a broad coverage of the enormous amount of published data in this field is unrewarding, this review will provide a brief, focused overview of the technology and a summary of recent studies of the most commonly used protein transduction domains and their potential as therapeutic agents for the treatment of cellular damage and the prevention of regulated cell death.

Citing Articles

TAT-RHIM: a more complex issue than expected.

Kolbrink B, Riebeling T, Teiwes N, Steinem C, Kalbacher H, Kunzendorf U Biochem J. 2022; 479(3):259-272.

PMID: 35015082 PMC: 8883498. DOI: 10.1042/BCJ20210677.


ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations.

Moral-Sanz J, Fernandez-Rojo M, Potriquet J, Mukhopadhyay P, Brust A, Wilhelm P Toxins (Basel). 2021; 13(2).

PMID: 33672955 PMC: 7918145. DOI: 10.3390/toxins13020146.


Efficient Therapeutic Delivery by a Novel Cell-Penetrating Peptide Derived from Acinus.

Habault J, Fraser C, Pasquereau-Kotula E, Born-Bony M, Marie-Cardine A, Poyet J Cancers (Basel). 2020; 12(7).

PMID: 32664285 PMC: 7408964. DOI: 10.3390/cancers12071858.


Combined Knockout of RIPK3 and MLKL Reveals Unexpected Outcome in Tissue Injury and Inflammation.

Moerke C, Bleibaum F, Kunzendorf U, Krautwald S Front Cell Dev Biol. 2019; 7:19.

PMID: 30842945 PMC: 6391322. DOI: 10.3389/fcell.2019.00019.


Glioma targeting peptide in combination with the P53 C terminus inhibits glioma cell proliferation in vitro.

Wang D, Guo M, Yu J, Wang X, Zhang Q, Yang X Cytotechnology. 2017; 70(1):153-161.

PMID: 28879517 PMC: 5809644. DOI: 10.1007/s10616-017-0122-3.


References
1.
Joliot A, Prochiantz A . Transduction peptides: from technology to physiology. Nat Cell Biol. 2004; 6(3):189-96. DOI: 10.1038/ncb0304-189. View

2.
Hotchkiss R, McConnell K, Bullok K, Davis C, Chang K, Schwulst S . TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol. 2006; 176(9):5471-7. DOI: 10.4049/jimmunol.176.9.5471. View

3.
Nagahara H, Snyder E, Ho A, Latham D, Lissy N, Ezhevsky S . Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med. 1998; 4(12):1449-52. DOI: 10.1038/4042. View

4.
Miyaji Y, Walter S, Chen L, Kurihara A, Ishizuka T, Saito M . Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab Dispos. 2011; 39(10):1946-53. DOI: 10.1124/dmd.111.040725. View

5.
Skehel J, Cross K, Steinhauer D, Wiley D . Influenza fusion peptides. Biochem Soc Trans. 2001; 29(Pt 4):623-6. DOI: 10.1042/bst0290623. View